California Trim Clinic review

California Trim Clinic names peptide evaluation options but publishes no peptide medication price. A free care-team call is separate from the required medical consultation, whose fee is unclear; pricing requests open chat, while other links lead to discovery booking. The menu also mixes compounds with a real mechanism and thin outcome data alongside several that FDA has not cleared for pharmacy compounding, and the site does not help you tell them apart.

California Trim Clinic is a Westlake Village, California practice offering telemedicine-first care with a platform credited to Heally. Its catalog includes NAD⁺, sermorelin, CJC-1295/ipamorelin, tesamorelin, BPC-157, TB-500, MOTS-c, GHK-Cu, epitalon, Semax/Selank, thymosin alpha-1, kisspeptin-10, elamipretide and blends, with PT-141, DSIP, GLOW/KLOW and KPV added to the main menu. The main page labels its listed preparations as subcutaneous injections; auxiliary menus also distinguish topical skin/hair products and oral options. A listing is an evaluation option, not guaranteed dispensability. Other services include GLP-1 care, hormones, teen weight loss and in-clinic body contouring.

A free initial care-team call by phone or video is separate from the required medical consultation; public pages do not establish its fee. History review and secure messaging are described, with reviews generally quoted at 24–48 hours after discovery and prescription delivery at 5–7 business days after approval. The terms describe administrative/technology services with independent clinicians licensed in the patient’s state. The peptide page names Dr. Sergio Naccarato; telemedicine separately names Dr. Lynda A. Szczech. These are provider-attributed identities and credentials, not independently verified assignments. The clinic claims all 50 states and licensed U.S. pharmacies, using 503A for peptides and 503A/503B in a general FAQ, but names no dispensing pharmacy or treating legal group. General eligibility is 18+, with guardian participation for teen weight loss and unspecified treatments requiring over 21; peptide-specific eligibility needs confirmation.

Peptide and NAD⁺ medication prices, vial quantities, prescribed supply, full initial charge and renewal terms are not published. The peptide page separately lists optional one-time labs: comprehensive panel $199, methylation panel $459 and a displayed Gallery by Grail test at $999. These do not establish mandatory peptide screening or inclusion in medication care. A free care-team call does not establish a free medical consultation; broader first-visit-free wording should be clarified. Pricing-information links open chat; Learn More/Explore links lead to discovery booking.

The cost page separately advertises semaglutide from $199/month and tirzepatide from $299/month. Its no-membership/no-auto-renew claims concern weight loss and do not settle peptide terms. Care is self-pay without insurance; HSA/FSA eligibility and Sezzle, Cherry or Affirm financing are conditional. Compounded orders cannot be returned once placed with the pharmacy, and refund requests must precede pharmacy processing, typically within a day. Unused prepaid-service refunds are subject to review and not guaranteed. Missing or stolen shipments must be reported within seven days for possible replacement.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The clinic says so plainly on its peptide page, and its own copy qualifies peptide care as available "when clinically appropriate and legally available". That qualifier matters here. BPC-157, TB-500, epitalon, MOTS-c, Semax, Selank, AOD-9604, CJC-1295, thymosin alpha-1 and injectable GHK-Cu were on FDA's Category 2 compounding list until April 2026 and are not yet cleared for pharmacy compounding; a July 2026 advisory vote to add some to the 503A bulks list is non-binding. Kisspeptin-10 and ipamorelin remain on FDA's Category 2 list. So ask which of the named peptides can actually be dispensed to you. On evidence, the menu spans very different tiers. Sermorelin, CJC-1295/ipamorelin and tesamorelin act on the growth-hormone axis, a real mechanism with thin long-term outcome data for wellness use. BPC-157, TB-500, GHK-Cu and most of the rest have essentially no controlled human outcome trials. Injected NAD⁺ has none; the oral precursors NR and NMN raise blood NAD⁺, which is a biomarker rather than a demonstrated benefit. Individual results vary.